Medicus Pharma (MDCX) announces that it has submitted an FDA Commissioner’s national priority voucher, CNPV, application on behalf of Skinject, SKNJCT-003, evaluating Doxorubicin Microneedle Array, D-MNA, to non-invasively treat basal cell carcinoma, BCC, of the skin. The submission includes a complete Statement of Interest outlining SkinJect’s alignment with FDA national priorities in cancer care access, affordability, and rare-disease needs.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX:
- Medicus Pharma Reports Q3 Loss Amid Strategic Growth
- Medicus Pharma Expands Phase 2 BCC Clinical Study to the UK
- Medicus Pharma receives full UK regulatory approvals to expand Phase 2 study
- Medicus Pharma Ltd’s Strategic Collaboration and Promising Phase 2 Results Justify Buy Rating
- Medicus Pharma Collaborates with Gorlin Syndrome Alliance for SKINJECT™ Access